|
Bleeding Disorders (All Ages), Service Specification (CP77), June 2022 (PDF, 343Kb)
|
|
Crizanlizumab for Preventing Sickle Cell Crisis in Sickle Cell Disease (SCD) in people aged 16 and over, Policy Position Statement (PP234), February 2023 (PDF, 281Kb)
|
|
Emicizumab as prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages), Policy Position Statement (PP167). November 2018 (PDF, 316Kb)
|
|
Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189). August 2019 (PDF, 246Kb)
|
|
Rituximab and Eculizumab for the Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in people with Hereditary Anaemias, Policy Position Statement (PP237), February 2023 (PDF, 438Kb)
|
|
Sickle Cell Disorders, Thalassaemia Disorders and other Rare Hereditary Anaemias, Service Specification (CP179). December 20201.0 (PDF, 494Kb)
|
|
Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease, Policy Position Statement (PP215), May 2021 (PDF, 329Kb)
|